Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
1
20%
Ph phase_4
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

terminated240%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

NCT02975349
completedphase_4

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

NCT02739542
completedphase_1

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

NCT04022473
completed

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

NCT02823951
terminated

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

NCT02218879

Clinical Trials (5)

Showing 5 of 5 trials
NCT02975349Phase 2

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Terminated
NCT02739542Phase 4

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

Completed
NCT04022473Phase 1

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Completed
NCT02823951

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Completed
NCT02218879

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5